Aprea Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Aprea Therapeutics

28/03/2024 12:00

* Aprea Therapeutics Inc  APRE.OQ  reported a quarterly
adjusted
loss of 92 cents​​ per share for the quarter ended in December,
identical to the same quarter last year.  The mean expectation
of three analysts for the quarter was for a loss of 77 cents per
share. Wall Street expected results to range from $-1.20 to -19
cents per share.
    * Revenue was $14.00 thousand​; analysts expected $110.00
thousand. 
    * Aprea Therapeutics Inc's reported EPS for the quarter was
a loss
of 92 cents​.
    * The company reported a quarterly loss of $3.44 million.
    * Aprea Therapeutics Inc shares had risen by 29.1% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Aprea
Therapeutics Inc is $16.00 
This summary was machine generated from LSEG data March 28 at
12:00 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.77          -0.92          Missed
 Sep. 30 2023      -1.16          -0.86          Beat
 Jun. 30 2023      -1.42          -0.87          Beat
 Mar. 31 2023      -1.50          -1.34          Beat